Alston Elliot Ltd has been acquired by Inflexion Private Equity
The shareholders of Alston Elliot, a leading provider of television sports graphics and data solutions, have sold the company to Inflexion Private Equity. Financial details have not been disclosed.
Alston Elliot was founded in 1992 and is globally recognized as one of the world’s leading providers of television sports graphics and data solutions to broadcasters and governing bodies. Its head office is located in the UK with thriving subsidiary companies in South Africa, India and Australia. Alston Elliot is the current official graphics supplier to Rugby World Cup, all ICC cricket events, BCCI’s international and domestic cricket, including the IPL, the Ashes, the Big Bash and Europe’s premier international rugby tournament, the Natwest 6 Nations.
Inflexion is one of the UK’s leading independent mid-market private equity houses, investing in high growth, entrepreneurial businesses with ambitious management teams, and working with them to deliver growth.
Oaklins Cavendish, based in the UK, advised the seller in this transaction.
Talk to the deal team
Related deals
Den Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Learn moreMicrofinanciera Fundeser has been sold to Grupo Financiero Atlántida
Incofin has successfully exited its investment in Microfinanciera Fundeser in Nicaragua through two of its funds: Rural Impulse Fund II (RIF II) and agRIF. It has sold 100% of its stake in Microfinanciera Fundeser to Grupo Financiero Atlántida through its subsidiary, Inversiones Tres Lagos.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn more